Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788827 | 0.89 | CNR2 (0.35) | MAPTKMT2ANPC1RAB9ACNR2 | |
| SCHEMBL20079064 | 0.86 | ALDH1A1 (0.41) | MAPTKMT2ANPC1RAB9ACNR2 | |
| SCHEMBL16006518 | 0.85 | MAPT (0.44) | MAPTKMT2ANPC1RAB9ACHUK | |
| SCHEMBL19788778 | 0.85 | CDK8 (0.36) | MAPTKMT2ANPC1RAB9ACNR2 | |
| SCHEMBL19788776 | 0.84 | MAPK14 (0.34) | MAPTKMT2ANPC1CNR2MAPK1 | |
| SCHEMBL22885167 | 0.84 | MAPT (0.33) | MAPTNPC1RAB9ACNR2MAPK1 | |
| SCHEMBL16158000 | 0.83 | KMT2A (0.43) | MAPTKMT2ANPC1RAB9ACHUK | |
| SCHEMBL19788770 | 0.83 | CYP3A4 (0.39) | MAPTKMT2ANPC1RAB9ACNR2 | |
| SCHEMBL19788828 | 0.83 | KDM4E (0.36) | MAPTKMT2ANPC1CNR2MAPK14 | |
| SCHEMBL19788774 | 0.83 | CASP1 (0.38) | MAPTKMT2ANPC1CNR2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| US-9951043-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | MAPT 170/4885KMT2A 3427/4885NPC1 50/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | MAPT 1547/4885KMT2A 4689/4885NPC1 8/4885 |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | MAPT 170/4885KMT2A 3427/4885NPC1 50/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | MAPT 170/4885KMT2A 3427/4885NPC1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.